Investment Summary

Ampersand Capital Partners Invests In NanoImaging Services

On June 12, 2023, growth capital firm Ampersand Capital Partners invested in business services company NanoImaging Services

Investment Highlights
  • This is Ampersand Capital Partners’ 1st transaction in the Business Services sector.
  • This is Ampersand Capital Partners’ 65th transaction in the United States.
  • This is Ampersand Capital Partners’ 11th transaction in California.

Investment Summary
Date 2023-06-12
Target NanoImaging Services
Sector Business Services
Investor(s) Ampersand Capital Partners
Deal Type Growth Capital

Target

NanoImaging Services

San Diego, California, United States
NanoImaging Services provides imaging services to the pharmaceutical, biotechnology, and nanotechnology communities. The company is committed to expanding its service capacity through microscope acquisition, workflow automation, recruitment and training of top talent, and development of new service offerings. Its state-of-the-art facilities include a range of electron microscopes, sample preparation equipment, and computational infrastructure to support structural biology and nanoparticle characterization workflows. NanoImaging Services was formed in 2007 and is based in San Diego, California.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 78 of 84
Sector (Business Services) 1 of 1
Type (Growth Capital) 24 of 24
State (California) 11 of 12
Country (United States) 65 of 69
Year (2023) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-05-02 P95

Leuven, Belgium

P95 is a global provider of clinical and epidemiology research solutions with a specialty focus on vaccines and infectious diseases. P95 offers a wide range of solutions including phase I-IV clinical studies, epidemiology, and RWE studies, in addition to scientific and clinical development consulting. It provides end-to-end services including study start-up, clinical monitoring, sample management, medical monitoring and pharmacovigilance, qualitative research, medical writing, data management, biostatistics, and IT. P95 was founded in 2011 and is based in Leuven, Belgium.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-08-17 AcuraBio

Darra, Australia

AcuraBio provides recombinant proteins and vaccines, and complex live biotherapeutic products to customers on the leading edge in emerging therapeutics. AcuraBio is based in Darra, Australia.

Sell -
Mergr

Product

Company

Legal